www.bioss.com.cn
400-901-9800
sales@bioss.com.cn
support@bioss.com.cn

Product Details

Product name:	**Anti-BCMA & CD3 (Linvoseltamab Biosimilar)**	**SKU:**	**BIO0976SM**
Target Name:	**BCMA & CD3**	**Size:**	**100ug/ 1mg/ 5mg**
Target Uniprot:	**Q02223 & P07766**	**Concentration:**	**Lyophilized**
Clone#:	**Linvoseltamab (Bispecific)**	**Isotype:**	**IgG-like**
Reactivity:	**Human**	**Calculated M.W.:**	**145.78 kDa**
Application:	**ELISA, Bioactivity: FACS, Functional assay, Research in vivo**	**Endotoxin:**	**<0.001 EU/ug**
Formulation:	**100 mM Pro-Ac 20mM Arg pH 5.0**	**Conjugation:**	**None**
Storage:	**-20°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.**	**Expression System:**	**CHO**
Reconstitution:	**Dissolve with sterile ddH₂O**	**Purification:**	**Protein A**

Data

Purity: SDS-PAGE



Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab)is 97.71%, determined by SEC-HPLC.

ELISA



Linvoseltamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. Ashown in fig, Linvoseltamab bound to huBCMA-ECD-His, and the EC50 was 0.096 nM .

Bioactivity: FACS



Linvoseltamab bound to Jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , andest by flow cytometry. As shown in fig, Linvoseltamab bound to Jurket cells, and the EC50 was 11.160 nM.

Bioactivity: FACS



Linvoseltamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Linvoseltamab bound to huBCMA-HEK293 cells, and the EC50 was 2.486 nM.

Function: Luciferase



Co-incubation of Linvoseltamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Linvoseltamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.678 nM.